Gibbs, J. P., Doshi, S., Kuchimanchi, M., Grover, A., Emery, M. G., Dodds, M. G., . . . Blom, D. (2016). Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). J Clin Pharmacol.
Chicago-стиль цитированияGibbs, John P., et al. "Impact of Target‐Mediated Elimination On the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)." J Clin Pharmacol 2016.
MLA-цитированиеGibbs, John P., et al. "Impact of Target‐Mediated Elimination On the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)." J Clin Pharmacol 2016.